Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Toxicol Pathol ; 37(3): 293-305, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19380840

ABSTRACT

In carcinogenicity studies with PPAR gamma and alpha/gamma agonists, urinary bladder tumors have been reported in Harlan Sprague-Dawley (HSD) and Charles River Sprague-Dawley (SD) but not Wistar (WI) rats, with urolithiasis purported to be the inciting event. In two 3-month studies, the authors investigated strain-related differences in urine composition by sampling urine multiple times daily. Urine pH, electrolytes, creatinine, protein, citrate and oxalate levels, and serum citrate were assessed; urine sediment was analyzed by scanning electron microscopy and energy dispersive x-ray spectroscopy. HSD rats had significantly higher urine calcium than SD or WI rats, primarily as calcium phosphate-containing precipitate. When compared to SD rats, HSD rats had lower urine volume, higher urine protein, and a comparable (week 4) to lower (week 13) burden of MgNH(4)PO(4) aggregates. Relative to WI rats, HSD rats had higher urine protein and magnesium and lower serum and urine citrate. Overall, the susceptibility to urolithiasis in male rats was HSD > SD > WI; this was likely due to strain-related differences in the amount of urine protein (a nidus for crystal formation), lithogenic ions, citrate (an inhibitor of lithogenesis), and/or volume. Strain-related differences in urine composition need to be considered when interpreting the outcome of studies with compounds that alter urine composition.


Subject(s)
Urinalysis , Urolithiasis/chemically induced , Animals , Calcium/urine , Calcium Phosphates/urine , Citrates/blood , Citrates/urine , Creatinine/urine , Electrolytes/urine , Hydrogen-Ion Concentration , Magnesium/urine , Magnesium Compounds/urine , Male , Microscopy, Electron, Scanning , Oxalates/urine , Phosphates/urine , Proteinuria/chemically induced , Rats , Rats, Sprague-Dawley , Rats, Wistar , Species Specificity , Spectrometry, X-Ray Emission/methods , Struvite
2.
J Am Assoc Lab Anim Sci ; 48(2): 144-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19383209

ABSTRACT

A novel therapeutic compound was found to induce bladder tumors in male rats. Given the location of the tumors and the increased amounts of calcium- and magnesium-containing solids found in the urine of treated animals, we hypothesized that tumorigenesis was secondary to urine crystal formation rather than a direct effect of the drug on urothelium. To investigate the basis for the response, a method of acidifying rodent urine was needed. This study tested the efficacy of 1% dietary NH(4)Cl in reducing the urinary pH of male mice. After 1 wk, urinary pH (mean +/- SD) at 1 h after light onset was 7.51 +/- 0.32 among controls compared with 6.21 +/- 0.31 for the NH(4)Cl-fed group. After 2 wk of supplementation, urinary pH was 7.78 +/- 0.41 for controls and 6.20 +/- 0.30 for the NH(4)Cl-fed group. To investigate whether the time of collection altered urinary pH, samples also were collected 8 h after the start of the light cycle on the day of the 2-wk collection. Urinary pH was 7.12 +/- 0.28 for the control group and 5.80 +/- 0.23 for the NH(4)Cl-fed mice. The pH differences between control and NH(4)Cl-fed groups and the differences in pH within groups at 1 and 8 h were statistically significant. Dietary NH(4)Cl is an effective urinary acidifier for mice. When evaluating the pH of mouse urine, care should be taken to compare samples collected at the same time after the start of the light cycle.


Subject(s)
Acid-Base Equilibrium/drug effects , Ammonium Chloride/administration & dosage , Animal Feed , Urine/chemistry , Animals , Hydrogen-Ion Concentration/drug effects , Male , Mice , Mice, Inbred Strains , Specific Pathogen-Free Organisms
3.
J Am Assoc Lab Anim Sci ; 47(2): 71-5, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18351725

ABSTRACT

Rodent toxicology studies have historically been performed in wire-bottom cages, but the 1996 Guide for the Care and Use of Laboratory Animals recommends solid-bottom caging with bedding. Some investigators have expressed concern that changing to solid-bottom cages would interfere with technicians' ability to detect clinical signs. To test this hypothesis, rats were housed in both types of caging and given compounds to induce a variety of subtle clinical signs common to toxicology studies including chromodacryorrhea, soft stool, stereotypic behaviors, mild hypoactivity, abnormal postures, and discolored urine. For one comparison, fecal pellets were removed to simulate decreased production of feces. Technicians, blinded from knowing which animals had been treated, observed the rats and recorded the clinical signs they detected. The technicians who administered the treatments verified that clinical signs were present before and after the blinded technicians made their observations. The number of animals observed with clinical signs divided by the number of animals verified with signs was calculated for each compound and compared between the cage types by using the Fisher Exact Test. The only statistically significant difference observed was a diminished ability to detect discolored, dark urine from rats in wire-bottom cages. These results suggest that concerns about technical staff's inability to detect clinical signs in toxicity tests should not prevent investigators from using solid-bottom cages with bedding.


Subject(s)
Animal Husbandry/methods , Animal Technicians , Diagnostic Techniques and Procedures/veterinary , Housing, Animal , Laboratory Animal Science/methods , Animals , Behavior, Animal , Constipation/diagnosis , Constipation/veterinary , Humans , Lacrimal Apparatus Diseases/diagnosis , Lacrimal Apparatus Diseases/veterinary , Male , Rats , Rats, Sprague-Dawley , Specific Pathogen-Free Organisms , Toxicity Tests/methods
4.
Toxicol Sci ; 98(1): 258-70, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17426106

ABSTRACT

The carcinogenic potential of muraglitazar, a dual human peroxisome proliferator-activated receptor alpha/gamma agonist, was evaluated in 2-year studies in mice (1, 5, 20, and 40 mg/kg) and rats (1, 5, 30, and 50 mg/kg). Benign gallbladder adenomas occurred at low incidences in male mice at 20 and 40 mg/kg (area under the curve [AUC] exposures > or = 62 times human exposure at 5 mg/day) and were considered drug related due to an increased incidence of gallbladder mucosal hyperplasia at these doses. There was a dose-related increased incidence of transitional cell papilloma and carcinoma of the urinary bladder in male rats at 5, 30, and 50 mg/kg (AUC exposures > or = 8 times human exposure at 5 mg/day). At 30 and 50 mg/kg, the urinary bladder tumors were accompanied by evidence of increased urine solids. Subsequent investigative studies established that the urinary bladder carcinogenic effect was mediated by urolithiasis rather than a direct pharmacologic effect on urothelium. Incidences of subcutaneous liposarcoma in male rats and subcutaneous lipoma in female rats were increased at 50 mg/kg (AUC exposures > or = 48 times human exposure at 5 mg/day) and attributed, in part, to persistent pharmacologic stimulation of preadipocytes. Toxicologically relevant nonneoplastic changes in target tissues included thinning of cortical bone in mice and hyperplastic and metaplastic adipocyte changes in mice and rats. Considering that muraglitazar is nongenotoxic, the observed tumorigenic effects in mice and rats have no established clinical relevance since they occurred at either clinically nonrelevant exposures (gallbladder and adipose tumors) or by a species-specific mechanism (urinary bladder tumors).


Subject(s)
Carcinogens , Glycine/analogs & derivatives , Hypoglycemic Agents/toxicity , Oxazoles/toxicity , PPAR alpha/agonists , PPAR gamma/agonists , Animals , Carcinogenicity Tests , Dose-Response Relationship, Drug , Female , Glycine/pharmacokinetics , Glycine/toxicity , Hypoglycemic Agents/pharmacokinetics , Male , Mice , Mice, Inbred ICR , Neoplasms/chemically induced , Neoplasms/epidemiology , Neoplasms/pathology , Oxazoles/pharmacokinetics , Rats , Rats, Sprague-Dawley , Survival Analysis , Urinalysis
5.
Toxicol Sci ; 96(1): 58-71, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17132713

ABSTRACT

Muraglitazar, a PPARalpha/gamma dual agonist, was dosed orally to rats once daily for 13 weeks to evaluate urinary and urothelial changes of potential relevance to urinary bladder tumorigenesis. Groups of 17 young or aged rats per sex were fed a normal or 1% NH4Cl-supplemented diet and were dosed with 0, 1, or 50 mg/kg muraglitazar. Lithogenic ions and sediment were profiled from freshly voided urine samples collected 24 h after dosing, and drug exposures were measured. Urinary citrate, oxalate, and epidermal growth factor (EGF) were assayed from 18-h urine collections. Urothelium was assessed by light microscopy, scanning electron microscopy, and BrdU and TUNEL immunohistochemistry. When fed a normal diet, urine pH was higher in males (above 6.5). Urine volume/body weight was greater in females. Urine soluble/total calcium and magnesium and phosphorus/creatinine ratios were lower in male rats fed a normal diet. Urine citrate levels were decreased and oxalate was increased in young male rats treated with 50 mg/kg muraglitazar compared to age/sex/diet-matched controls. No changes in urine sediment were detected 24 h after dosing. In young male rats treated with 50 mg/kg on normal diet, multifocal urothelial necrosis and proliferation were observed, whereas urothelial apoptosis and urine EGF levels were unchanged compared to age/sex/diet-matched controls. Urothelial necrosis and proliferation were not correlated to systemic or urinary drug exposures and were prevented by dietary acidification. These data suggest that muraglitazar-associated changes in urine composition predispose to urothelial cytotoxicity and proliferation in the urinary bladder of young male rats and that urine sediment must be profiled at multiple daily timepoints to fully qualify drug-induced changes in urine composition.


Subject(s)
Glycine/analogs & derivatives , Oxazoles/toxicity , PPAR alpha/agonists , PPAR gamma/agonists , Peroxisome Proliferators/toxicity , Urinary Bladder/drug effects , Age Factors , Animals , Apoptosis/drug effects , Calcium/urine , Cell Proliferation/drug effects , Citrates/urine , Creatinine/urine , Dose-Response Relationship, Drug , Epidermal Growth Factor/urine , Female , Glycine/toxicity , Glycine/urine , Hyperplasia , Magnesium/urine , Male , Oxalates/urine , Oxazoles/urine , Peroxisome Proliferators/urine , Phosphorus/urine , Rats , Rats, Sprague-Dawley , Sex Factors , Time Factors , Urinary Bladder/ultrastructure , Urine/chemistry , Urothelium/drug effects
6.
J Cell Biol ; 152(6): 1159-68, 2001 Mar 19.
Article in English | MEDLINE | ID: mdl-11257117

ABSTRACT

The release of biogenic amines from large dense core vesicles (LDCVs) depends on localization of the vesicular monoamine transporter VMAT2 to LDCVs. We now find that a cluster of acidic residues including two serines phosphorylated by casein kinase 2 is required for the localization of VMAT2 to LDCVs. Deletion of the acidic cluster promotes the removal of VMAT2 from LDCVs during their maturation. The motif thus acts as a signal for retention on LDCVs. In addition, replacement of the serines by glutamate to mimic phosphorylation promotes the removal of VMAT2 from LDCVs, whereas replacement by alanine to prevent phosphorylation decreases removal. Phosphorylation of the acidic cluster thus appears to reduce the localization of VMAT2 to LDCVs by inactivating a retention mechanism.


Subject(s)
Amino Acid Motifs , Biogenic Monoamines/metabolism , Exocytosis/physiology , Glycoproteins , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/metabolism , Membrane Proteins , Membrane Transport Proteins , Neuropeptides , Protein Sorting Signals , Protein Transport/physiology , Secretory Vesicles/metabolism , Amino Acid Sequence , Animals , Biogenic Monoamines/chemistry , Brefeldin A/pharmacology , Carrier Proteins/metabolism , Cell Fractionation , Chromogranins , Immunoblotting , Membrane Glycoproteins/genetics , Microscopy, Fluorescence , Molecular Sequence Data , Mutagenesis, Site-Directed , PC12 Cells , Phosphorylation , Protein Synthesis Inhibitors/pharmacology , Proteins/metabolism , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Secretory Vesicles/chemistry , Secretory Vesicles/drug effects , Vesicular Biogenic Amine Transport Proteins , Vesicular Monoamine Transport Proteins , Vesicular Transport Proteins , trans-Golgi Network/metabolism
7.
J Cell Biol ; 149(2): 379-96, 2000 Apr 17.
Article in English | MEDLINE | ID: mdl-10769030

ABSTRACT

Vesicular transport proteins package classical neurotransmitters for regulated exocytotic release, and localize to at least two distinct types of secretory vesicles. In PC12 cells, the vesicular acetylcholine transporter (VAChT) localizes preferentially to synaptic-like microvesicles (SLMVs), whereas the closely related vesicular monoamine transporters (VMATs) localize preferentially to large dense core vesicles (LDCVs). VAChT and the VMATs contain COOH-terminal, cytoplasmic dileucine motifs required for internalization from the plasma membrane. We now show that VAChT undergoes regulated phosphorylation by protein kinase C on a serine (Ser-480) five residues upstream of the dileucine motif. Replacement of Ser-480 by glutamate, to mimic the phosphorylation event, increases the localization of VAChT to LDCVs. Conversely, the VMATs contain two glutamates upstream of their dileucine-like motif, and replacement of these residues by alanine conversely reduces sorting to LDCVs. The results provide some of the first information about sequences involved in sorting to LDCVs. Since the location of the transporters determines which vesicles store classical neurotransmitters, a change in VAChT trafficking due to phosphorylation may also influence the mode of transmitter release.


Subject(s)
Carrier Proteins/metabolism , Cytoplasmic Granules/physiology , Cytoplasmic Granules/ultrastructure , Membrane Transport Proteins , Neuropeptides , Vesicular Transport Proteins , Amino Acid Substitution , Animals , COS Cells , Carrier Proteins/chemistry , Carrier Proteins/genetics , Cell Fractionation , Cell Membrane/metabolism , Centrifugation, Density Gradient , Cloning, Molecular , Glutamic Acid , Leucine , Membrane Glycoproteins/metabolism , Mutagenesis, Site-Directed , PC12 Cells , Phosphorylation , Point Mutation , Protein Kinase C/metabolism , Rats , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Serine , Serotonin/metabolism , Synaptic Vesicles/physiology , Synaptic Vesicles/ultrastructure , Vesicular Acetylcholine Transport Proteins , Vesicular Biogenic Amine Transport Proteins
8.
Trends Cell Biol ; 9(9): 356-63, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10461189

ABSTRACT

Many psychoactive drugs influence the transport of neurotransmitters across biological membranes, suggesting that the physiological regulation of neurotransmitter transport might contribute to normal and perhaps abnormal behaviour. Over the past few years, molecular characterization of the neurotransmitter transporters has enabled investigation of their subcellular location and regulation. The analysis of location suggests that membrane trafficking has an important role in the normal function of these proteins. One of the major regulatory mechanisms also involves changes in localization that might contribute to synaptic plasticity. This article discusses recent work on the membrane trafficking of neurotransmitter transporters and its role in regulating their activity.


Subject(s)
Carrier Proteins/metabolism , Membrane Glycoproteins/metabolism , Nerve Tissue Proteins/metabolism , Neurotransmitter Agents/metabolism , Synaptic Transmission/physiology , Affect/physiology , Animals , Biological Transport , Carrier Proteins/antagonists & inhibitors , Carrier Proteins/classification , Cells, Cultured , Dogs , Humans , Illicit Drugs/pharmacology , Ion Transport , Membrane Glycoproteins/antagonists & inhibitors , Mice , Mice, Neurologic Mutants , Nerve Tissue Proteins/antagonists & inhibitors , Neurons/metabolism , Neurons/ultrastructure , PC12 Cells , Rats , Signal Transduction , Swine
9.
Toxicol Appl Pharmacol ; 159(1): 9-17, 1999 Aug 15.
Article in English | MEDLINE | ID: mdl-10448120

ABSTRACT

Azaspiranes are cationic amphiphilic compounds that are active in a number of models of autoimmune disease and transplantation. Repeated administration of cationic amphiphiles induces phospholipid accumulation in a variety of species. The present study was conducted to explore the mechanism of phospholipid accumulation in rats caused by treatment with the novel azaspirane, SK&F 106615 (atiprimod). Atiprimod inhibited the activities of partially purified phospholipases A(2) and C, but not D, in a noncompetitive manner in vitro. Treatment of rats for 28 days with 10 mg/kg/day of atiprimod increased the contents of arachidonate-containing molecular species within plasmalogen subclasses of hepatic phosphatidylcholine and phosphatidylethanolamine. In contrast, diacyl-linked species were not affected, indicating a selective effect upon an hepatic plasmalogen-selective phospholipase A(2). Taken together, the data suggest that the beneficial effects of atiprimod in autoimmune diseases may involve inhibition of phospholipase A(2) and C activities. Further, the data suggest that atiprimod is a selective inhibitor of plasmalogen-selective phospholipase A(2) in vivo.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Macrophages, Alveolar/metabolism , Phospholipases/antagonists & inhibitors , Phospholipids/metabolism , Spiro Compounds/pharmacology , Animals , Arachidonic Acid/metabolism , Binding, Competitive , In Vitro Techniques , Male , Phosphatidylcholines/metabolism , Phosphatidylethanolamines/metabolism , Phospholipases/classification , Rats , Rats, Sprague-Dawley
10.
J Biol Chem ; 273(28): 17351-60, 1998 Jul 10.
Article in English | MEDLINE | ID: mdl-9651318

ABSTRACT

Specific transport proteins mediate the packaging of neurotransmitters into secretory vesicles and consequently require targeting to the appropriate intracellular compartment. To identify residues in the neuron-specific vesicular monoamine transporter (VMAT2) responsible for endocytosis, we examined the effect of amino (NH2-) and carboxyl (COOH-)-terminal mutations on steady state distribution and internalization. Deletion of a critical COOH-terminal domain sequence (AKEEKMAIL) results in accumulation of VMAT2 at the plasma membrane and a 50% reduction in endocytosis. Site-directed mutagenesis shows that replacement of the isoleucine-leucine pair within this sequence by alanine-alanine alone reduces endocytosis by 50% relative to wild type VMAT2. Furthermore, the KEEKMAIL sequence functions as an internalization signal when transferred to the plasma membrane protein Tac, and the mutation of the isoleucine-leucine pair also abolishes internalization of this protein. The closely related vesicular acetylcholine transporter (VAChT) contains a similar di-leucine sequence within the cytoplasmic COOH-terminal domain that when mutated results in accumulation of VAChT at the plasma membrane. The VAChT di-leucine sequence also confers internalization when appended to two other proteins and in one of these chimeras, conversion of the di-leucine sequence to di-alanine reduces the internalization rate by 50%. Both VMAT2 and VAChT thus use leucine-based signals for efficient endocytosis and as such are the first synaptic vesicle proteins known to use this motif for trafficking.


Subject(s)
Acetylcholine/metabolism , Carrier Proteins/metabolism , Endocytosis , Leucine/metabolism , Membrane Glycoproteins/metabolism , Membrane Transport Proteins , Neuropeptides , Neurotransmitter Agents/metabolism , Vesicular Transport Proteins , Amino Acid Sequence , Animals , COS Cells , Carrier Proteins/chemistry , Carrier Proteins/genetics , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/genetics , Membrane Proteins/metabolism , Molecular Sequence Data , Mutagenesis, Site-Directed , Sequence Homology, Amino Acid , Vesicular Acetylcholine Transport Proteins , Vesicular Biogenic Amine Transport Proteins , Vesicular Monoamine Transport Proteins
11.
J Histochem Cytochem ; 45(5): 743-53, 1997 May.
Article in English | MEDLINE | ID: mdl-9154162

ABSTRACT

We introduce here a new fluorescence microscopy technique for en face analysis of the atherosclerotic fatty streaks (FS). This technique is semiquantitative and has the sensitivity and resolution to map lipids to individual cells in FS less than 100 microns in diameter. New Zealand White rabbits were fed an atherogenic diet for up to 26 weeks. Aortas were fixed in formalin and stained en bloc with the fluorescent dyes Nile red and filipin. Fluorescent staining was validated by correlating microfluorimetric and biochemical measurements of the lipid content in FS. To determine the cell types associated with the different staining patterns, FS were also evaluated by transmission electron microscopy (TEM) and immunohistochemistry (IH). Correlation of microfluorimetry, TEM, IH, and biochemical data indicated that regions rich in non-esterified cholesterol stained with filipin and fluoresced blue owing to accumulations of lipid vesicles and/or cholesterol crystals. Regions rich in neutral and polar lipids stained with Nile red and fluoresced yellow or orange, respectively, owing to accumulations of lipids in both macrophages and smooth muscle cells (SMC). Digital overlays of the filipin and Nile red images revealed that larger lesions (> 0.5 mm diameter) had a "nested" distribution of lipids, with a blue (filipin) fringe surrounding an orange (Nile red) fringe surrounding a yellow (Nile red) center.


Subject(s)
Arteriosclerosis/metabolism , Lipids/analysis , Microscopy, Fluorescence , Animals , Arteriosclerosis/pathology , Biopsy , Disease Models, Animal , Rabbits , Time Factors
12.
Article in English | MEDLINE | ID: mdl-9246500

ABSTRACT

Molecular cloning of the transport proteins involved in packaging monoamines and ACh into secretory vesicles has implicated their activity in neural degeneration as well as signaling. Future studies will explore further the mechanism of active transport, its regulation, and the membrane trafficking of the proteins with the long-term goal of understanding how the regulation of transmitter release and, in particular, quantal size influences information processing and behavior. In addition, the bioenergetics of vesicular GABA and glutamate transport suggests that the proteins responsible for these activities may belong to a distinct gene family.


Subject(s)
Biogenic Monoamines/metabolism , Carrier Proteins/metabolism , Synaptic Vesicles/metabolism , Animals , Biogenic Monoamines/physiology , Biological Transport, Active , Carrier Proteins/physiology , Humans , Synaptic Transmission/physiology , Synaptic Vesicles/physiology
13.
J Histochem Cytochem ; 43(10): 1071-8, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7560885

ABSTRACT

Macrophage-derived foam cells are a prominent component of developing atherosclerotic lesions. We describe an in vitro model of foam cell formation which mimics some aspects of the evolution of foam cells in mature atherosclerotic lesions. Thioglycollate-elicited mouse peritoneal macrophages were incubated with copper-oxidized LDL (ox-LDL) for periods up to 168 hr. Identifiable foam cells were present after incubation with ox-LDL at 24, 72, and 168 hr. Control cells incubated without ox-LDL did not form foam cells. Fluorescence microscopy after staining with Nile red exhibited progressive accumulation of lipids, and transmission electron microscopy (TEM) showed distinct ultrastructural changes over time. Macrophages at 24 hr had a few non-membrane-bound lipid droplets but were otherwise identical to control cells. These lipid droplets fluoresced yellow-gold after Nile red staining. After 72 hr of incubation with ox-LDL, in addition to increased numbers of non-membrane-bound lipid inclusions, macrophages contained membrane-bound multilamellar lipoid structures. These multilamellar structures corresponded to areas of reddish-orange fluorescence after Nile red staining. In macrophages incubated with ox-LDL for 168 hr, the amount of cellular lipid was further increased and cholesterol crystal profiles were apparent within some multilamellar lipoid structures. Biochemical analysis showed that the total cholesterol content steadily increased over 168 hr. The increase in total cholesterol was accompanied by a dramatic increase in free cholesterol between 72 and 168 hr. These results demonstrate that long-term incubation of macrophages with ox-LDL increased lipid deposition in cultured cells and that, under the conditions studied, cholesterol crystals formed in macrophage foam cells. Moreover, this system allows investigation of the evolution of foam cells showing some characteristics of those found in atherosclerotic lesions.


Subject(s)
Cholesterol/analysis , Foam Cells/cytology , Lipoproteins, LDL/pharmacology , Macrophages, Peritoneal/cytology , Macrophages, Peritoneal/physiology , Animals , Cells, Cultured , Cholesterol/metabolism , Foam Cells/drug effects , Foam Cells/ultrastructure , Humans , Lipid Peroxidation , Lysosomes/drug effects , Lysosomes/ultrastructure , Macrophages, Peritoneal/drug effects , Mice , Microscopy, Electron/methods , Microscopy, Fluorescence/methods , Oxidation-Reduction , Thiobarbituric Acid Reactive Substances/analysis , Thioglycolates
14.
Toxicol Appl Pharmacol ; 130(2): 316-21, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7871542

ABSTRACT

Cationic amphiphilic drugs (CADs) are structurally characterized by hydrophobic ring structures and hydrophilic side chains. Studies have demonstrated that repeated administration of CADs to experimental animals and humans may induce phospholipid (PL) accumulation within the cells of various tissues. The immunomodulatory azaspiranes are novel CADs with beneficial effects in a number of animal models of autoimmune disease and transplantation. Although the mechanism of action of these compounds is unclear, efficacy in all of the disease models is accompanied by the generation of suppressor cell (SC) activity in various lymphoid organs. SK&F 105685 (N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine+ ++ hydrochloride) and two analogs, SK&F 106615 and SK&F 103811, were compared with chlorphentermine and chloroquine for their ability to induce PL accumulation and SC activity. Oral administration of SK&F 105685 and SK&F 106615 caused PL accumulation in bronchoalveolar lavage macrophages (AM) but to a far lesser extent (three- to fivefold) than chlorphentermine. Neither the immunologically unreactive azaspirane SK&F 103811 nor chloroquine affected PL levels. AM from rats treated with SK&F 105685 or SK&F 106615 expressed more potent SC activity than chlorphentermine. Thus, SC activity did not correlate with the extent of PL accumulation. Neither SK&F 103811 nor chloroquine induced SC activity. AM from SK&F 105685-treated rats had an enhanced ability to kill the opportunistic pathogen Candida albicans in vitro indicating that there was no impairment of macrophage-dependent host defense mechanisms.


Subject(s)
Bronchi/metabolism , Macrophages, Alveolar/metabolism , Phospholipids/metabolism , Spiro Compounds/pharmacology , Animals , Bronchi/drug effects , Candida albicans/drug effects , Chloroquine/pharmacology , Chlorphentermine/pharmacology , Immunosuppressive Agents/pharmacology , Inclusion Bodies/metabolism , Macrophages, Alveolar/drug effects , Male , Pulmonary Alveoli/drug effects , Pulmonary Alveoli/metabolism , Rats , Rats, Inbred Lew , Structure-Activity Relationship , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...